On April 7, 2025, the company convened a Q1 business performance review meeting at its Liuyang base. The session was chaired by Shen Fanshun, the company's Party branch secretary and chairman, with all mid-level and senior management members in attendance.

The meeting comprehensively reviewed the first-quarter operational results, analyzed the current internal and external challenges, identified existing issues and shortcomings, and established specific targets and actionable measures to achieve the mid-year goal of 'halfway through the year, halfway through the tasks.'

The company maintained steady growth in its first-quarter operations, with multiple key metrics showing significant improvement. Sales volume, production output, and production yield rates all saw notable year-on-year and quarter-on-quarter increases. Production costs continued to decline, and progress in asset revitalization has been achieved, laying a solid foundation for meeting annual targets. While acknowledging these accomplishments, the meeting also identified challenges that may hinder further development.

Regarding the next phase of work, Shen Fanshun emphasized that all company cadres and employees must unify their thinking, strengthen accountability, adopt problem-oriented approaches, implement targeted and immediate measures, and execute tasks with a sense of urgency to ensure successful completion of objectives. For key tasks in the second quarter, Shen Fanshun outlined five priorities: 1) Precise efforts should be made in sales of new traditional Chinese medicine decoctions, focusing on developing and maintaining high-quality clients. Sales strategies should be continuously optimized based on market changes and product characteristics, accelerating the expansion of the "Chen Shan He" series of food-and-medicine dual-purpose products; 2) Production management should aim for full capacity with the "two increases and three decreases" principle, ensuring stable product supply. The company should intensify efforts to identify, cultivate, and incentivize "craftsman-type" talents; 3) Continuously improve management efficiency through implementing energy consumption control systems, operating digital platforms for production, supply, and sales, and applying for "Green Factory" certification; 4) Maintain R&D innovation by accelerating research on key technical standards and processes for new traditional Chinese medicine decoctions to achieve early and significant breakthroughs; 5) Accelerate key special projects such as in-house preparation development and revitalization of foreign-funded assets according to scheduled timelines.